Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2004 Jun;59(6):459–464. doi: 10.1136/thx.2003.013573

Plasma 9α,11ß-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma

G Bochenek 1, E Nizankowska 1, A Gielicz 1, M Swierczynska 1, A Szczeklik 1
PMCID: PMC1747024  PMID: 15170023

Abstract

Background: Prostaglandin D2 (PGD2) is a major cyclooxygenase product generated by activated mast cells during an allergic response. Assessment of PGD2 and its metabolites in patients with asthma has mostly been performed in urine, bronchoalveolar lavage fluid and induced sputum, whereas human plasma determinations have been performed only sporadically.

Methods: In 32 patients with allergic asthma and 50 healthy non-allergic controls, baseline plasma and urinary levels of 9α,11ß-PGF2, a primary PGD2 metabolite, were assessed by gas chromatography/mass spectrometry. Serum tryptase levels were measured by fluoroenzyme immunoassay and urinary leukotriene E4 (LTE4) by ELISA. In a subgroup of 10 asthmatics (randomly selected from the 32 study patients) in whom bronchial allergen challenges with specific allergens (Dermatophagoides pteronyssinus, n = 4, mixed grass pollens, n = 6) were carried out, measurements were taken both before and after provocation.

Results: At baseline no significant differences between mean plasma and urinary levels of the PGD2 metabolite and serum tryptase levels were found in asthmatics or controls. Asthmatic patients had significantly higher urinary LTE4 levels. Allergen challenge resulted in a significant early increase in the mean plasma 9α,11ß-PGF2 level and only a borderline but significant increase in the urinary 9α,11ß-PGF2 level within 2 hours after provocation. The challenge did not produce statistically significant changes in serum tryptase levels. Urinary LTE4 levels remained significantly increased 4 hours after provocation.

Conclusions: PGD2 is actively involved in the early asthmatic response to allergens. Measurement of 9α,11ß-PGF2 release into plasma rather than urine following allergen challenge is a sensitive marker of enhanced PGD2 synthesis, most probably due to mast cell activation.

Full Text

The Full Text of this article is available as a PDF (141.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Awad J. A., Morrow J. D., Roberts L. J., 2nd Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation. J Allergy Clin Immunol. 1994 May;93(5):817–824. doi: 10.1016/0091-6749(94)90371-9. [DOI] [PubMed] [Google Scholar]
  2. Beasley C. R., Robinson C., Featherstone R. L., Varley J. G., Hardy C. C., Church M. K., Holgate S. T. 9 alpha,11 beta-prostaglandin F2, a novel metabolite of prostaglandin D2 is a potent contractile agonist of human and guinea pig airways. J Clin Invest. 1987 Mar;79(3):978–983. doi: 10.1172/JCI112909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beasley R., Hovel C., Mani R., Robinson C., Varley J., Holgate S. T. Comparative vascular effects of histamine, prostaglandin (PG) D2 and its metabolite 9 alpha,11 beta-PGF2 in human skin. Clin Allergy. 1988 Nov;18(6):619–627. doi: 10.1111/j.1365-2222.1988.tb02914.x. [DOI] [PubMed] [Google Scholar]
  4. Bochenek Grazyna, Nagraba Krzysztof, Nizankowska Ewa, Szczeklik Andrzej. A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol. 2003 Apr;111(4):743–749. doi: 10.1067/mai.2003.1387. [DOI] [PubMed] [Google Scholar]
  5. Brightling C. E., Ward R., Woltmann G., Bradding P., Sheller J. R., Dworski R., Pavord I. D. Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma. Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):878–882. doi: 10.1164/ajrccm.162.3.9909064. [DOI] [PubMed] [Google Scholar]
  6. Gervais F. G., Cruz R. P., Chateauneuf A., Gale S., Sawyer N., Nantel F., Metters K. M., O'neill G. P. Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP. J Allergy Clin Immunol. 2001 Dec;108(6):982–988. doi: 10.1067/mai.2001.119919. [DOI] [PubMed] [Google Scholar]
  7. Kumlin M., Dahlén B. The challenge procedure influences the extent of allergen-induced urinary excretion of leukotriene E4. Clin Exp Allergy. 2000 Apr;30(4):585–589. doi: 10.1046/j.1365-2222.2000.00738.x. [DOI] [PubMed] [Google Scholar]
  8. Kumlin M., Stensvad F., Larsson L., Dahlén B., Dahlén S. E. Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans. Clin Exp Allergy. 1995 May;25(5):467–479. doi: 10.1111/j.1365-2222.1995.tb01079.x. [DOI] [PubMed] [Google Scholar]
  9. Liston T. E., Roberts L. J., 2nd Metabolic fate of radiolabeled prostaglandin D2 in a normal human male volunteer. J Biol Chem. 1985 Oct 25;260(24):13172–13180. [PubMed] [Google Scholar]
  10. MacDermot J., Kelsey C. R., Waddell K. A., Richmond R., Knight R. K., Cole P. J., Dollery C. T., Landon D. N., Blair I. A. Synthesis of leukotriene B4, and prostanoids by human alveolar macrophages: analysis by gas chromatography/mass spectrometry. Prostaglandins. 1984 Feb;27(2):163–179. doi: 10.1016/0090-6980(84)90071-6. [DOI] [PubMed] [Google Scholar]
  11. Manning P. J., Rokach J., Malo J. L., Ethier D., Cartier A., Girard Y., Charleson S., O'Byrne P. M. Urinary leukotriene E4 levels during early and late asthmatic responses. J Allergy Clin Immunol. 1990 Aug;86(2):211–220. doi: 10.1016/s0091-6749(05)80068-5. [DOI] [PubMed] [Google Scholar]
  12. Medrala W., Małolepszy J., Wolańczyk-Medrala A., Wrzyszcz M., Liebhart E., Kraus-Filarska M., Dobek R. Is mast cell activation during asthmatic reaction reflected in the circulation? J Investig Allergol Clin Immunol. 1995 Nov-Dec;5(6):343–346. [PubMed] [Google Scholar]
  13. Monneret G., Gravel S., Diamond M., Rokach J., Powell W. S. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood. 2001 Sep 15;98(6):1942–1948. doi: 10.1182/blood.v98.6.1942. [DOI] [PubMed] [Google Scholar]
  14. Murray J. J., Tonnel A. B., Brash A. R., Roberts L. J., 2nd, Gosset P., Workman R., Capron A., Oates J. A. Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med. 1986 Sep 25;315(13):800–804. doi: 10.1056/NEJM198609253151304. [DOI] [PubMed] [Google Scholar]
  15. O'Sullivan S., Dahlén B., Dahlén S. E., Kumlin M. Increased urinary excretion of the prostaglandin D2 metabolite 9 alpha, 11 beta-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J Allergy Clin Immunol. 1996 Aug;98(2):421–432. doi: 10.1016/s0091-6749(96)70167-7. [DOI] [PubMed] [Google Scholar]
  16. O'Sullivan S., Mueller M. J., Dahlén S. E., Kumlin M. Analyses of prostaglandin D2 metabolites in urine: comparison between enzyme immunoassay and negative ion chemical ionisation gas chromatography-mass spectrometry. Prostaglandins Other Lipid Mediat. 1999 May;57(2-3):149–165. doi: 10.1016/s0090-6980(98)00076-8. [DOI] [PubMed] [Google Scholar]
  17. O'Sullivan S., Roquet A., Dahlén B., Dahlén S., Kumlin M. Urinary excretion of inflammatory mediators during allergen-induced early and late phase asthmatic reactions. Clin Exp Allergy. 1998 Nov;28(11):1332–1339. doi: 10.1046/j.1365-2222.1998.00368.x. [DOI] [PubMed] [Google Scholar]
  18. Obata T., Nagakura T., Kammuri M., Masaki T., Maekawa K., Yamashita K. Determination of 9 alpha, 11 beta-prostaglandin F2 in human urine and plasma by gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl. 1994 May 13;655(2):173–178. doi: 10.1016/0378-4347(94)00100-6. [DOI] [PubMed] [Google Scholar]
  19. Oelz O., Oelz R., Knapp H. R., Sweetman B. J., Oates J. A. Biosynthesis of prostaglandin D2. 1. Formation of prostaglandin D2 by human platelets. Prostaglandins. 1977 Feb;13(2):225–234. doi: 10.1016/0090-6980(77)90004-1. [DOI] [PubMed] [Google Scholar]
  20. Schwartz L. B., Metcalfe D. D., Miller J. S., Earl H., Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med. 1987 Jun 25;316(26):1622–1626. doi: 10.1056/NEJM198706253162603. [DOI] [PubMed] [Google Scholar]
  21. Sladek K., Szczeklik A. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur Respir J. 1993 Mar;6(3):391–399. [PubMed] [Google Scholar]
  22. Smith C. M., Christie P. E., Hawksworth R. J., Thien F., Lee T. H. Urinary leukotriene E4 levels after allergen and exercise challenge in bronchial asthma. Am Rev Respir Dis. 1991 Dec;144(6):1411–1413. doi: 10.1164/ajrccm/144.6.1411. [DOI] [PubMed] [Google Scholar]
  23. Tanaka K., Ogawa K., Sugamura K., Nakamura M., Takano S., Nagata K. Cutting edge: differential production of prostaglandin D2 by human helper T cell subsets. J Immunol. 2000 Mar 1;164(5):2277–2280. doi: 10.4049/jimmunol.164.5.2277. [DOI] [PubMed] [Google Scholar]
  24. Taylor G. W., Taylor I., Black P., Maltby N. H., Turner N., Fuller R. W., Dollery C. T. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet. 1989 Mar 18;1(8638):584–588. doi: 10.1016/s0140-6736(89)91611-5. [DOI] [PubMed] [Google Scholar]
  25. Tsikas D. Application of gas chromatography-mass spectrometry and gas chromatography-tandem mass spectrometry to assess in vivo synthesis of prostaglandins, thromboxane, leukotrienes, isoprostanes and related compounds in humans. J Chromatogr B Biomed Sci Appl. 1998 Oct 9;717(1-2):201–245. doi: 10.1016/s0378-4347(98)00210-2. [DOI] [PubMed] [Google Scholar]
  26. Wang D., Smitz J., Waterschoot S., Clement P. An approach to the understanding of the nasal early-phase reaction induced by nasal allergen challenge. Allergy. 1997 Feb;52(2):162–167. doi: 10.1111/j.1398-9995.1997.tb00970.x. [DOI] [PubMed] [Google Scholar]
  27. Wenzel S. E., Fowler A. A., 3rd, Schwartz L. B. Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma. Am Rev Respir Dis. 1988 May;137(5):1002–1008. doi: 10.1164/ajrccm/137.5.1002. [DOI] [PubMed] [Google Scholar]
  28. Yeh Tsu F., Lin Yuh J., Lin Hung C., Huang Chao C., Hsieh Wu S., Lin Chyi H., Tsai Cheng H. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med. 2004 Mar 25;350(13):1304–1313. doi: 10.1056/NEJMoa032089. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES